- Status required for completion
- Fully attended
- Language
- English - United States (en_us)
- Event booking
- Over
- Trainer
- Elton Machholz 'Report Account'
Status
Times
Rooms
Calendar
- Status required for completion
- Fully attended
- Language
- English - United States (en_us)
- Event booking
- Over
Status
Times
Status
Session over
Times
, - Timezone: UTC
- Status required for completion
- Fully attended
- Language
- English - United States (en_us)
- Event booking
- Over
- Trainer
- Aurore Varela, Rachel Bulock
- Details
In August of 2022, ICH Guidance on carcinogenicity testing of pharmaceuticals was revised (ICH S1B(R1). The addendum introduces a more comprehensive and integrative approach to assessing human carcinogenic risk of pharmaceuticals. This integrative approach describes specific WoE criteria that in some cases may provide an adequate assessment of human carcinogenicity risk without data from a 2-year rat carcinogenicity study. The addendum also provides for use of a plasma exposure ratio-based approach to high dose selection in the rasH2-Tg mouse model. The goal of the seminar is to provide CRL colleagues an overview of these changes in carcinogenicity testing paradigms for small molecule therapeutics.
Status
Times
Rooms
Facilitators